Patent ID: 7498032

Claim:
A method for activating or augmenting an immune response of a subject having a CD40 positive cancer, comprising: administering to the subject an amount of an unconjugated antibody comprising light chain variable region complementarity determining regions having the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and heavy chain variable region complementarity determining regions having the amino acid sequences of SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, which antibody (i) immunospecifically binds CD40, (ii) increases the binding of CD40 ligand to cell surface CD40 by at least 45%, and (iii) is a chimeric or humanized form, or an antibody fragment thereof, of monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, which amount is such that the immune response of the subject is activated or augmented.